ZANTAC "SEE YOUR DOCTOR" ADS GENERATED 581,000 PATIENT VISITS
Executive Summary
ZANTAC "SEE YOUR DOCTOR" ADS GENERATED 581,000 PATIENT VISITS as a result of the announcements that began running on television in April 1988, according to Peter Parks, of the New York City advertising agency William Douglas McAdams that designed the ads. Addressing a Regulatory Affairs Professionals Society meeting Oct. 16 in Washington, D.C., Parks said that the target audience for the campaign was 20 mil. viewers, of which "12 mil. saw the ad and 581,000 visited their physician." Parks noted that the Zantac ads targeted chronic antacid users, with the reasoning that if patients are "self-medicating" with antacids, creating "a hyperawareness" that heavy antacid use can lead to damage to the esophagus "generates patient visits." As with the Zantac ads, Park said, direct-to-consumer advertising "should be generally educational, not promotional, and thus in most cases should not include the mention of the specific drug by brandname." William Douglas McAdams also designed Pfizer's "Partners in HealthCare" ads, which in 1982 were one of the first attempts by the drug industry to produce FDA-accepted direct-to-consumerads in support of prescription products. Those ads focused on symptoms of diabetes. According to Parks, 40% of the consumer audience questioned recalled the diabetes ad, and 15% of the audience associated Pfizer with the campaign. In addition, 100,000 physicians and 15,000 pharmacists requested material from Pfizer. Pfizer's products include Diabinese (chlorpropamide) for diabetes.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth